EffecMed Private Limited is a health-technology startup incubated at IIT Bombay and supported by Ipca Laboratories Ltd., with a clear mandate: to deliver advanced, cost-effective biomaterials-based devices for bone regeneration and repair. The company combines academic rigor with industrial scale to address unmet clinical needs through science-driven innovation. Its latest product, Dentafuse, exemplifies this approach. EffecMed engineers Dentafuse using a composite of nano-hydroxyapatite (HA) integrated with both synthetic and natural polymers, including gelatin and carboxymethyl chitin.
Together, these materials create a highly supportive biological environment that facilitates the delivery of a natural spectrum of bone growth factors. As a result, Dentafuse functions as a sterilized, highly porous, cancellous-type biomaterial with haemostatic and viscoelastic properties. Moreover, it relies on organic and inorganic constituents with well-established safety profiles, reinforcing its clinical reliability.
In an exclusive interaction with The Interview World at Expodent International India 2025, Dr Kunal Khanna, Co-founder and Chief Executive Officer of EffecMed Pvt. Ltd., along with Ashwini Shedge, Vice President – Sales and Marketing at Ipca Laboratories Ltd., provided deeper insights into Dentafuse. They articulated its distinctive value proposition, detailed its material and functional characteristics, assessed its market potential, and outlined its applicability beyond dental use, including orthopedic indications. They also emphasized what sets Dentafuse apart in an increasingly competitive biomaterials landscape.
The following are the key takeaways from their in-depth and thought-provoking discussion.
Q: Could you elaborate on the innovation, core functionality, and unique value proposition of your product, Dentafuse?
A: Dentafuse stands apart as a truly distinctive solution in bone regeneration. Built on patented technology developed and transferred from IIT Bombay, it reflects EffecMed’s role as the original innovator behind both its composition and its manufacturing process. This proprietary approach delivers a clear and defensible advantage over conventional alternatives.
Unlike traditional bone putties or particulate grafts, Dentafuse actively accelerates bone regeneration. It conforms tightly to the defect site, regardless of shape or irregularity, ensuring precise placement and optimal stability. At the same time, it forms a uniform, interconnected, and highly predictable bone scaffold that supports consistent healing.
Crucially, Dentafuse resorbs completely within approximately three months, leaving no residual gaps. As it resolves, it promotes faster and more complete bone formation, resulting in a seamless and biologically integrated repair.
Q: What are the key properties and characteristics of Dentafuse?
A: Dentafuse offers a set of distinctive properties that translate directly into clinical efficiency and cost savings. First, it significantly reduces operative time. The surgeon can simply hydrate the material in any suitable fluid, trim it chairside or on the surgical table, and insert it directly into defects of any size or geometry.
Second, Dentafuse eliminates the need for a barrier membrane. Because it conforms tightly to the defect and remains securely in place, it provides inherent stability without additional coverage. Consequently, it lowers procedural complexity while reducing overall costs for both the clinician and the patient.
Q: How do you assess the market potential of this product?
A: The market opportunity is substantial. Dentafuse offers broad applicability across clinical scenarios wherever bone defects or bone loss occur. As a result, its potential extends well beyond a single indication or specialty. At present, the company is focused on introducing and scaling the product within the Indian market, while systematically evaluating expansion across all relevant use cases.
Q: Can this product be used in the treatment of orthopedic conditions?
A: Yes, Dentafuse presents a significant opportunity in the orthopedic segment. The company plans to launch the orthopedic variant within the next six months. In the interim, EffecMed is actively evaluating the product through clinical investigations at leading institutions, including AIIMS New Delhi, AIIMS Bhubaneswar, Maulana Azad Medical College, and KEM Hospital, Mumbai.
These ongoing evaluations underscore both the product’s readiness and its clinical promise. Based on current evidence, the upcoming launch is expected to deliver strong and measurable outcomes in orthopedic applications.
Q: Does this product have competitors, or is it unique in the market?
A: Several competitors operate in the market across similar clinical indications. However, Dentafuse clearly differentiates itself through a combination of structural and material innovations that others do not offer.
Most notably, Dentafuse features a monolithic architecture, a design attribute absent in competing products. In addition, its unique composition integrates natural and synthetic polymer composites in a way that no alternative currently matches. This formulation confers distinct viscoelastic properties, which provide superior handling, stability, and performance at the defect site. Taken together, these attributes create a competitive edge that remains unmatched in the current landscape.
